Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

NCT02674750 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Interventions

DRUG: CUDC-907

Sponsor

Curis, Inc.